Gilead's Positive Phase II Data On Quad Pill For HIV Eases Analysts Concerns
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With two novel components included in Gilead's investigational four-drug, fixed-dose combination pill for HIV, the company has a full clinical program ahead of it - but the first Phase II results offer early signs of promise